GLP-1 Maker Sued Over Ads; Vaginal Estrogen; Melinda Gates Talks Perimenopause

Novo Nordisk sued rival drugmaker Eli Lilly, alleging false advertising claims about relative weight-loss drug performance. (Reuters via NBC News) GLP-1 drug use surged from 2017 to 2022, jumping 230% in adults with diabetes and 643% in those without, national data indicated. (Journal of the American Heart Association) Meanwhile, Truveta data identified tirzepatide (Mounjaro, Zepbound) as the most popular anti-obesity and anti-diabetic medication in June 2026. A preprint study flagged signals of frailty in seniors taking tirzepatide for weight loss. (Reuters via Yahoo!) A Sanofi survey found that 26% of people with a first-degree relative with type 1 diabetes didn't think they were at increased risk. The Federal Trade Commission said CVS Caremark settled a lawsuit alleging the pharmacy benefit manager artificially inflated the price of insulin and impeded access to the treatment. A single Revita duodenal ablation cut post-GLP-1 weight regain by roughly 40% at 1 year compared with a sham procedure, developer Fractyl Health reported. Medicaid-insured women were less likely to receive menopausal hormone therapy than those with private insurance, national survey data found. (JAMA Network Open) The New York Times highlighted key considerations for women exploring vaginal estrogen for menopause symptoms. Melinda French Gates told CBS News it took three doctors to properly diagnose and treat her perimenopause. Eli Lilly partnered with Oura to integrate smart-ring biometric data with personalized insights for GLP-1 users. Puberty blockers were linked to some reduced mental health disparities in transgender youth ages 10 to 17 years, nationwide claims data suggested. (JAMA Network Open) Obesity risk among Hispanic and Asian foreign-born adults increased with longer duration of U.S. residence, cross-sectional survey data indicated. (Annals of Internal Medicine) A post hoc analysis of SOUL trial data showed oral semaglutide (Rybelsus) yielded better cardiovascular benefits in patients with higher baseline HbA1c and greater HbA1c reductions. (Journal of Clinical Endocrinology & Metabolism)